Log in

NASDAQ:IMDZImmune Design Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
0.00 (0.00 %)
(As of 04/2/2019)
Today's Range
Now: $5.85
50-Day Range
MA: $5.85
52-Week Range
Now: $5.85
Average Volume374,216 shs
Market Capitalization$282.96 million
P/E RatioN/A
Dividend YieldN/A
Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma. The company is also developing CA21, a multi-targeting prime boost for the treatment of multiple solid tumors; and ZVex-IL12 for the treatment of TBD tumors. In addition, its technologies are used in the fields of infectious and allergic diseases. The company has license agreements with California Institute of Technology, University of North Carolina at Chapel Hill, TheraVectys SA, Infectious Disease Research Institute, MedImmune LLC, and Sanofi; and a collaboration agreement with Sanofi Pasteur. Immune Design Corp. was founded in 2008 and is headquartered in Seattle, Washington.
Read More
Immune Design logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.82 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:IMDZ



Sales & Book Value

Annual Sales$2.20 million
Book Value$1.91 per share


Net Income$-54,760,000.00
Net Margins-2,483.00%


Market Cap$282.96 million
Next Earnings DateN/A

Receive IMDZ News and Ratings via Email

Sign-up to receive the latest news and ratings for IMDZ and its competitors with MarketBeat's FREE daily newsletter.

Immune Design (NASDAQ:IMDZ) Frequently Asked Questions

How were Immune Design's earnings last quarter?

Immune Design Corp (NASDAQ:IMDZ) issued its earnings results on Wednesday, August, 1st. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.01. The biotechnology company earned $0.76 million during the quarter, compared to analysts' expectations of $0.64 million. Immune Design had a negative net margin of 2,483.00% and a negative return on equity of 49.56%. View Immune Design's earnings history.

Has Immune Design been receiving favorable news coverage?

News coverage about IMDZ stock has been trending positive on Wednesday, InfoTrie reports. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Immune Design earned a media sentiment score of 2.2 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about Immune Design.

Who are some of Immune Design's key competitors?

What other stocks do shareholders of Immune Design own?

Who are Immune Design's key executives?

Immune Design's management team includes the following people:
  • Dr. Carlos V. Paya, CEO, Pres & Director (Age 60)
  • Mr. Stephen R. Brady, Exec. VP of Strategy & Fin. (Age 49)
  • Dr. Jan Henrik Ter Meulen, Chief Scientific Officer (Age 56)
  • Sylvia Wheeler, Investor Relations Officer
  • Dr. Wayne R. Gombotz, Chief Devel. Officer (Age 60)

What is Immune Design's stock symbol?

Immune Design trades on the NASDAQ under the ticker symbol "IMDZ."

What is Immune Design's stock price today?

One share of IMDZ stock can currently be purchased for approximately $5.85.

How big of a company is Immune Design?

Immune Design has a market capitalization of $282.96 million and generates $2.20 million in revenue each year. The biotechnology company earns $-54,760,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis. Immune Design employs 48 workers across the globe.

What is Immune Design's official website?

The official website for Immune Design is www.immunedesign.com.

How can I contact Immune Design?

Immune Design's mailing address is 1616 EASTLAKE AVENUE EAST SUITE 310, SEATTLE WA, 98102. The biotechnology company can be reached via phone at 206-682-0645 or via email at [email protected]

This page was last updated on 7/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.